ASRT - assertiotx.com Debt to Book Capitalization Ratio

Brandmark of Assertio Holdings (ASRT)

Effective management at Assertio Holdings, Inc. (ASRT) has optimized costs and focused on acquiring profitable brands. This debt-to-equity structure chart demonstrates financial stability, where the current parameter equals 0.51. This strategy helps offset generic pressure through the acquisition of niche drugs, although the gradual expiration of patents for pain medications is steadily weakening the business's defensive barriers.

Assertio (ASRT) - Debts to Book Value from 07/04/2022 to 06/27/2026
Brand item of Assertio

The portfolio expansion strategy of Assertio Holdings, Inc. (ASRT) is reflected in the ratio of the company's total debt to its equity capital. This indicator assesses the degree of financial autonomy by comparing total liabilities against equity. The calculation is based on dividing all borrowed funds by the value of net equity. Low values confirm resilience to default but may signal a conservative approach to investment. It is critical for the investor to maintain a balance between security and the pace of business growth.

Who Assertio Holdings, Inc. competes with

Debt to Book Value BIIB (Biogen Inc.)|neurocrine.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Regencell Bioscience Holdings Limited (RGC)|AXSM: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio ACAD|Xenon Corp (XENE) - Debts to Book Value|VKTX (Viking Therapeutics) - Debts to Book Capitalization|Debts to Book Capitalization SUPN|CPRX (Catalyst Pharmaceuticals, Inc.) - Debt to Book Capitalization Ratio|Debts to Net Assets DNLI (Denali)|Debt to Book Capitalization Ratio HRMY|Debts to Net Assets Biohaven Corp BHVN|AMLX (Amylyx Pharmaceuticals) - Debts to Book Capitalization|TRVI: Debts to Book Value|Debt to Book Capitalization Ratio Praxis Precision Medicines, Inc. PRAX|Debt to Net Assets Ratio Anavex|CeriBell Corp (CBLL) - Debt to Book Value|Debt to Book Capital prothena.com|ALEC (Alector, Inc.) - Debts to Book Capitalization|Debts to Net Assets ANNX (annexonbio.com)|OMER: Debt to Book Capitalization Ratio|NGNE - Debts to Book Value|Debt to Book Value AC Immune Corp (ACIU)|VYGR - Debt to Net Assets Ratio|Debts to Book Capitalization Neumora Therapeutics NMRA|SCLX (scilexholding.com) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio TVGN (Tevogen Bio)|Debts to Book Value ACOG|Debt to Book Capitalization Ratio Cognition Therapeutics (CGTX)|Debt to Book Capitalization Ratio Inhibikase Pharma (IKT)|SAVA - Debts to Book Capitalization|Debt to Book Value Ratio Coya Therapeutics Inc COYA|Debts to Book Capitalization VTGN (VistaGen Therapeutics Inc)|OVID: Debts to Net Assets|Debt to Book Capitalization Ratio Acumen Pharma|CervoMed Corporation (CRVO) - Debt to Book Value Ratio|Alterity Therapeutics Ltd. - Debts to Book Capitalization|Debt to Net Assets CLNN|PEPG (PepGen Inc.) - Debt to Book Capitalization Ratio|Debts to Net Assets Jupiter Neurosciences, Inc. JUNS|Debt to Book Value Relmada|Debt to Net Assets Ratio Annovis Bio Corporation ANVS|Debts to Book Capitalization GRCE (Grace Tx)|AIFF: Debts to Net Assets|Debt to Book Capitalization Ratio anewmeds.com|NeuroSense Therapeutics Ltd. (NRSN) - Debt to Book Value Ratio|Debts to Book Capitalization RVPH|Debt to Book Value MetaVia, Inc. (MTVA)|NRXS (NeurAxis, Inc.) - Debt to Book Value|Debts to Net Assets heliusmedical.com (HSDT)|Debts to Book Capitalization PASG (Passage Bio)|Neuphoria Therapeutics, Inc. - Debts to Book Capitalization|Debt to Book Capitalization Ratio NERV (Minerva Neurosciences Corp)|ATHA: Debts to Net Assets|Debt to Book Capitalization Ratio Addex Therapeutics ADXN|Debt to Net Assets Ratio Alzamend Neuro|Cyclerion Therapeutics Inc. (CYCN) - Debt to Book Value|Debt to Book Capital PTIX|Debt to Book Capitalization Ratio Pasithea Therapeutics KTTA|Debt to Book Value Ratio cortigent.com (CRGT)|ATXI: Debts to Book Capitalization|BCLI - Debts to Book Value|Cara Therapeutics - Debt to Book Value|CHRO: Debts to Book Capitalization|Debt to Book Capitalization Ratio eliemtx.com ELYM|ITCI (Intra-Cellular Therapies, Inc.) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio LBPH (Longboard Pharmaceuticals)|Debts to Book Value marinuspharma.com|Debts to Book Capitalization NKGN|Debts to Book Capitalization NRBO (NeuroBo Pharmaceuticals Inc)|Debt to Book Capitalization Ratio SAGE|Synaptogenix, Inc - Debts to Net Assets|Debt to Book Capitalization Ratio TRVN (Trevena, Inc.)|VIGL - Debts to Net Assets|Debts to Book Capitalization WENA|CERE (Cerevel Therapeutics Inc) - Debts to Book Value